Literature DB >> 18645425

Novel immunomodulating agents for Graves orbitopathy.

Luigi Bartalena1, Adriana Lai, Emanuele Compri, Claudio Marcocci, Maria Laura Tanda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18645425     DOI： 10.1097/IOP.0b013e318179f8a5

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN： 0740-9303            Impact factor:   1.746


× No keyword cloud information.
  4 in total

1.  Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique.

Authors:  Raymond S Douglas; Angelo Tsirbas; Mark Gordon; Diana Lee; Nicole Khadavi; Helene Chokron Garneau; Robert A Goldberg; Kenneth Cahill; Peter J Dolman; Victor Elner; Steve Feldon; Mark Lucarelli; Jimmy Uddin; Michael Kazim; Terry J Smith; Dinesh Khanna
Journal:  Arch Ophthalmol       Date:  2009-09

2.  Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy.

Authors:  K A Ponto; T Diana; H Binder; N Matheis; S Pitz; N Pfeiffer; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2015-03-04       Impact factor: 4.256

3.  Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy.

Authors:  Dinesh Khanna; Kelvin K L Chong; Nikoo F Afifiyan; Catherine J Hwang; Diana K Lee; Helene Chokron Garneau; Robert A Goldberg; Christine H Darwin; Terry J Smith; Raymond S Douglas
Journal:  Ophthalmology       Date:  2009-10-08       Impact factor: 12.079

Review 4.  Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis.

Authors:  Changjun Wang; Qingyao Ning; Kai Jin; Jiajun Xie; Juan Ye
Journal:  BMC Ophthalmol       Date:  2018-02-17       Impact factor: 2.209
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.